EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Mini-review: The market growth of diagnostic and therapeutic monoclonal antibodies – SARS CoV-2 as an example

Yasmine El Abd, Ashraf Tabll, Robert Smolic, Martina Smolic

Human Antibodies · 18.02.2022 · 30 (1) · 15-24

DOI: 10.3233/hab-211513 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Human Antibodies, erschienen am 18.02.2022. Verfasst von Yasmine El Abd und 3 weiteren Autor:innen. Beteiligte Einrichtung: Microbial Biotechnology Department, Biotechnology Research Institute, National Research Centre, Dokki, Egypt. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, COVID-19. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 61 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The emergence of novel viruses poses severe challenges to global public health highlighting the crucial necessity for new antivirals. MAIN BODY: Monoclonal antibodies (mAbs) are immunoglobulins that bind to a single epitope. Mouse mAbs are generated by classic hybridoma technology and are mainly used for immunodiagnostics. For immunotherapy, it is critical to use monoclonal antibodies in their human form to minimize adverse reactions. They have been successfully used to treat numerous illnesses, accordingly, an increasing number of mAbs, with high potency against emerging viruses is the target of every biopharmaceutical company. The diagnostic and therapeutic mAbs market grows rapidly into a multi-billion-dollar business. Biopharmaceuticals are innovative resolutions which revolutionized the treatment of significant chronic diseases and malignancies. Currently, a variety of therapeutic options that include antiviral medications, monoclonal antibodies, and immunomodulatory agents are available for the management of COVID-19. SHORT CONCLUSION: The invasion of mAbs in new medical sectors will increase the market magnitude as it is expected to generate revenue of about 300 billion $ by 2025. In the current mini-review, the applications of monoclonal antibodies in immune-diagnosis and immunotherapy will be demonstrated, particularly for COVID-19 infection and will focus mainly on monoclonal antibodies in the market.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalCOVID-19AnimalsAntibodies, ViralEpitopesHumansHybridomasMiceSARS-CoV-2

Stichwörter der Autor:innen

COVID-19Monoclonal antibodiesSARS CoV-2immunodiagnosticsimmunotherapymarket trends

Substanzen

Antibodies, MonoclonalAntibodies, ViralEpitopes

Autor:innen und Institutionen

  • Microbial Biotechnology Department, Biotechnology Research Institute, National Research Centre, Dokki, Egypt.
  • Technology and Innovation Commercialization Office (TICO), National Research Centre, Dokki, Egypt.
  • Department of Immunology, Egypt Center for Research and Regenerative Medicine (ECRRM), Cairo, Egypt.
  • Faculty of Medicine Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.
  • Division of Gastroenterology/Hepatology, Department of Medicine, University Hospital Osijek, Osijek, Croatia.
  • Faculty of Dental Medicine and Health Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.

Zitieren

APA

El Abd, Y., Tabll, A., Smolic, R., & Smolic, M. (2022). Mini-review: The market growth of diagnostic and therapeutic monoclonal antibodies – SARS CoV-2 as an example. Human Antibodies, 30(1), 15-24. https://doi.org/10.3233/hab-211513

Vancouver

El Abd Y, Tabll A, Smolic R, Smolic M. Mini-review: The market growth of diagnostic and therapeutic monoclonal antibodies – SARS CoV-2 as an example. Human Antibodies. 2022;30(1):15-24. doi:10.3233/hab-211513

BibTeX
@article{ElAbd2022,
  author = {El Abd, Yasmine and Tabll, Ashraf and Smolic, Robert and Smolic, Martina},
  title = {Mini-review: The market growth of diagnostic and therapeutic monoclonal antibodies – SARS CoV-2 as an example},
  journal = {Human Antibodies},
  year = {2022},
  volume = {30},
  number = {1},
  pages = {15--24},
  doi = {10.3233/hab-211513}
}
Kostenlos starten →